Targeting intratumoral androgens: statins and beyond

by Michael T. Schweizer, Evan Y. Yu
Published 2016-09-01

AR-Signaling in Human Malignancies: Prostate Cancer and Beyond

by Michael T. Schweizer, Evan Y. Yu
Published 2017-01-01

The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions

by Evan Y Yu, William K Oh
Published 2014-06-01

Hormone levels following surgical and medical castration: defining optimal androgen suppression

by Michael T Schweizer, Michael L Hancock, Robert H Getzenberg, Evan Y Yu
Published 2018-01-01

Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies.

by Laura S Graham, Bruce Montgomery, Heather H Cheng, Evan Y Yu, Peter S Nelson, Colin Pritchard, Stephanie Erickson, Ajjai Alva, Michael T Schweizer
Published 2020-01-01

Whole-Body [¹⁸F]-Fluoride PET SUV Imaging to Monitor Response to Dasatinib Therapy in Castration-Resistant Prostate Cancer Bone Metastases: Secondary Results from ACRIN...

by Mark Muzi, Finbarr O’Sullivan, Timothy G. Perk, John P. Muzi, David A. Mankoff, Robert Jeraj, Fenghai Duan, Evan Y. Yu
Published 2021-04-01

Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.

by Alexander S Carlson, Rigo I Acevedo, Daniel M Lim, Roman Gulati, Agnes Gawne, Alexandra O Sokolova, Heather H Cheng, Peter S Nelson, R Bruce Montgomery, Evan Y Yu, Michael T Schweizer
Published 2020-01-01

Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer

by Franklin C. Lee, William Harris, Heather H. Cheng, Jaideep Shenoi, Song Zhao, Junfeng Wang, Thomas Champion, Jason Izard, John L. Gore, Michael Porter, Evan Y. Yu, Jonathan L. Wright
Published 2013-01-01

Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer

by Alexander S. Carlson, Rigo I. Acevedo, Daniel M. Lim, Roman Gulati, Agnes Gawne, Alexandra O. Sokolova, Heather H. Cheng, Peter S. Nelson, R. Bruce Montgomery, Evan Y. Yu, Michael T. Schweizer, Alvaro Galli
Published 2020-01-01

A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.

by Michael T Schweizer, Kathleen Haugk, Jožefa S McKiernan, Roman Gulati, Heather H Cheng, Jessica L Maes, Ruth F Dumpit, Peter S Nelson, Bruce Montgomery, Jeannine S McCune, Stephen R Plymate, Evan Y Yu
Published 2018-01-01

Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.

by Michael T Schweizer, Kathleen Haugk, Jožefa S McKiernan, Roman Gulati, Heather H Cheng, Jessica L Maes, Ruth F Dumpit, Peter S Nelson, Bruce Montgomery, Jeannine S McCune, Stephen R Plymate, Evan Y Yu
Published 2018-01-01

Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database

by Gabriella Del Bene, Fabio Calabrò, Diana Giannarelli, Elizabeth R. Plimack, Lauren C. Harshman, Evan Y. Yu, Simon J. Crabb, Sumanta Kumar Pal, Ajjai S. Alva, Thomas Powles, Ugo De Giorgi, Neeraj Agarwal, Aristotelis Bamias, Sylvain Ladoire, Andrea Necchi, Ulka N. Vaishampayan, Günter Niegisch, Joaquim Bellmunt, Jack Baniel, Matthew D. Galsky, Cora N. Sternberg
Published 2018-11-01